{"filing":{"accession_number":"0001213900-26-098224","cik":"0002023016","ticker":"TTRX","company_name":"Turn Therapeutics Inc.","form":"8-K","filing_date":"2026-09-09","report_date":"2026-09-09","primary_document":"ea0304806-8k_turn.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2023016/000121390026098224/ea0304806-8k_turn.htm"},"events":[{"id":32220,"run_id":29601,"accession_number":"0001213900-26-098224","anchor_item_number":"7.01","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Turn Therapeutics announced the appointment of Robert R. Redfield, M.D., former CDC Director, as Chief Scientific Officer. The press release emphasizes his four decades of experience in immunology and infectious disease, his extensive scientific publications, and his prior leadership roles at the CDC and University of Maryland. This is a material executive appointment of a high-profile scientific leader to a named officer position at the company.","company_name":"Turn Therapeutics Inc.","ticker":"TTRX","filing_date":"2026-09-09","form":"8-K","submitted_at":null,"items":[{"id":35337,"accession_number":"0001213900-26-098224","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Turn Therapeutics announced the appointment of Robert R. Redfield, M.D., former CDC Director, as Chief Scientific Officer. The press release emphasizes his four decades of experience in immunology and infectious disease, his extensive scientific publications, and his prior leadership roles at the CDC and University of Maryland. This is a material executive appointment of a high-profile scientific leader to a named officer position at the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T12:11:37.184550+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35337,"accession_number":"0001213900-26-098224","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Turn Therapeutics announced the appointment of Robert R. Redfield, M.D., former CDC Director, as Chief Scientific Officer. The press release emphasizes his four decades of experience in immunology and infectious disease, his extensive scientific publications, and his prior leadership roles at the CDC and University of Maryland. This is a material executive appointment of a high-profile scientific leader to a named officer position at the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T12:11:37.184550+00:00","company_name":"Turn Therapeutics Inc.","ticker":"TTRX","filing_date":"2026-09-09"}]}